BGN and Hepatic fibrosis: Considering that GP73 could act as an indicator for both liver necroinflammation and liver fibrosis, other serum biomarkers such as biglycan, which is closely correlated with both liver necroinflammation and fibrosis, probably could be used as a noninvasive necroinflammation marker in NASH [40].